These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 172761)
1. Immunoassay of human plasma apolipoprotein B. Albers JJ; Cabana VG; Hazzard WR Metabolism; 1975 Dec; 24(12):1339-51. PubMed ID: 172761 [TBL] [Abstract][Full Text] [Related]
2. Assay of total plasma apolipoprotein B concentration in human subjects. Schonfeld G; Lees RS; George PK; Pfleger B J Clin Invest; 1974 May; 53(5):1458-67. PubMed ID: 4363408 [TBL] [Abstract][Full Text] [Related]
3. Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects. Marcoux C; Tremblay M; Fredenrich A; Jacques H; Krimbou L; Nakajima K; Davignon J; Cohn JS Atherosclerosis; 1998 Jul; 139(1):161-71. PubMed ID: 9699904 [TBL] [Abstract][Full Text] [Related]
4. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202 [TBL] [Abstract][Full Text] [Related]
5. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475 [TBL] [Abstract][Full Text] [Related]
6. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523 [TBL] [Abstract][Full Text] [Related]
7. Solid phase radioimmunoassay of apolipoprotein B (apo B) in normal human plasma. Thompson GR; Birnbaumer ME; Levy RI; Gotto AM Atherosclerosis; 1976; 24(1-2):107-18. PubMed ID: 182180 [TBL] [Abstract][Full Text] [Related]
8. Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension. Ryomoto KI; Suzuki M; Kanazawa A; Hasegawa M; Kimura Y; Yamamura T; Harano Y Am J Hypertens; 2000 Jun; 13(6 Pt 1):617-24. PubMed ID: 10912744 [TBL] [Abstract][Full Text] [Related]
9. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484 [TBL] [Abstract][Full Text] [Related]
10. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Chan DC; Watts GF; Somaratne R; Wasserman SM; Scott R; Barrett PHR Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1644-1655. PubMed ID: 29880491 [TBL] [Abstract][Full Text] [Related]
11. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Taskinen MR; Packard CJ; Shepherd J Diabetes; 1990 Sep; 39(9):1017-27. PubMed ID: 2200727 [TBL] [Abstract][Full Text] [Related]
12. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome. Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090 [TBL] [Abstract][Full Text] [Related]
13. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes. Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863 [TBL] [Abstract][Full Text] [Related]
14. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419 [TBL] [Abstract][Full Text] [Related]
15. Effects of short- and long-term growth hormone replacement on lipoprotein composition and on very-low-density lipoprotein and low-density lipoprotein apolipoprotein B100 kinetics in growth hormone-deficient hypopituitary subjects. Kearney T; de Gallegos CN; Proudler A; Parker K; Anayaoku V; Bannister P; Venkatesan S; Johnston DG Metabolism; 2003 Jan; 52(1):50-9. PubMed ID: 12524662 [TBL] [Abstract][Full Text] [Related]
16. APO low density lipoprotein localization. Intracranial and extracranial atherosclerotic lesions from human normolipoproteinemics and hyperlipoproteinemics. Hoff HF; Heideman CL; Gaubatz JW Arch Neurol; 1975 Sep; 32(9):600-5. PubMed ID: 169766 [TBL] [Abstract][Full Text] [Related]
17. Distribution of lipoproteins triglyceride and lipoprotein cholesterol in an adult population by age, sex, and hormone use- The Pacific Northwest Bell Telephone Company health survey. Wahl PW; Warnick GR; Albers JJ; Hoover JJ; Walden CE; Bergelin RO; Ogilvie JT; Hazzard WR; Knopp RH Atherosclerosis; 1981 Apr; 39(1):111-24. PubMed ID: 6941788 [TBL] [Abstract][Full Text] [Related]
20. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs. Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]